Difficult-to-treat-pediatric Crohn's disease: focus on adalimumab
{{output}}
Adalimumab is a fully humanized anti-tumor necrosis factor alpha monoclonal antibody that was recently granted regulatory approval in the USA for the treatment of moderate to severe Crohn's disease (CD) in children. Like infliximab, the first biologic agent us... ...